Application of 25-hydroxyvitamin D in preparation of disease activity evaluation kit for patients with Takayasu arteritis

A technology of hydroxyvitamins and Takayasu arteritis, which is applied in the field of preparation of disease activity evaluation kits for patients with Takayasu arteritis, can solve the problems of being unable to meet the clinical needs of accurately judging disease activity

Active Publication Date: 2021-04-13
北京豪思生物科技股份有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it cannot meet the clinical needs of accurately judging disease activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 25-hydroxyvitamin D in preparation of disease activity evaluation kit for patients with Takayasu arteritis
  • Application of 25-hydroxyvitamin D in preparation of disease activity evaluation kit for patients with Takayasu arteritis
  • Application of 25-hydroxyvitamin D in preparation of disease activity evaluation kit for patients with Takayasu arteritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] By detecting the concentration of 25(OH)D in the plasma of 126 patients with Takayasu arteritis and 154 healthy control subjects, the mean value of 25(OH)D in the plasma of 154 healthy control groups was 19.63ng / ml (range: 8.79 to 36.64ng / m1), and the level of plasma 25(OH)D in patients with Takayasu arteritis was significantly lower than that in healthy controls (p<0.01), and the average value was 16.29 (the numerical value here is to include active Takayasu arteritis patients and latent period Mean values ​​obtained from patients with Takayasu arteritis) ng / ml (range: 5.2 to 39.40 ng / m1).

[0053] When patients with Takayasu arteritis were divided into active phase and latent phase according to disease activity, the mean value of plasma 25(OH)D in active phase patients was 13.29 ng / ml (range: 5.2 to 30.05 ng / m1), while in The average value of patients in the incubation period was 21.25ng / ml (range: 14.92 to 39.40ng / m1), and the results of statistical analysis showed t...

Embodiment 2

[0060] In the treatment of patients with Takayasu arteritis, commonly used drugs are glucocorticoids and immunosuppressants. Hormone is still the main treatment drug for patients with active disease, but hormone therapy can cause adverse reactions such as osteoporosis, so patients using hormone therapy will be given vitamin D supplementation. So does vitamin D supplementation affect the association between 25(OH)D and disease activity? The present study found that vitamin D supplementation or no supplementation did not affect the correlation between 25(OH)D and disease activity. Such as figure 2 It was shown that whether the patients with Takayasu arteritis were supplemented with vitamin D or not, when the disease activity turned into the latent stage, the plasma 25(OH)D level rose to a cutoff value of 15.98ng / ml or more. When the active state of the disease turned to active, the 25(OH)D level decreased to below the cutoff value of 15.98ng / ml.

[0061] During the treatment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of 25-hydroxyvitamin D in preparing a kit for judging and / or assisting judging disease activity of patients with Takayasu arteritis. The invention also discloses a kit for judging and / or assisting judging disease activity of patients with Takayasu arteritis, which includes products for detecting the content of 25-hydroxyvitamin D in biological samples of Takayasu patients; the kit also includes A carrier that records the following judgment criteria: when the concentration of 25-hydroxyvitamin D in the biological sample is lower than 15.98ng / ml, it is determined that the patient is in the active stage of Takayasu arteritis; when the concentration of 25-hydroxyvitamin D in the biological sample If the concentration of D is equal to or higher than 15.98ng / ml, it is determined that the patient is in the latent stage of Takayasu arteritis.

Description

technical field [0001] The invention relates to the application of 25-hydroxyvitamin D in the preparation of a disease activity evaluation kit for patients with Takayasu arteritis. Background technique [0002] At present, there are no good serological indicators for judging disease activity in patients with Takayasu arteritis, except for imaging data. [0003] The etiology of Takayasu arteritis is still unclear. Pathological studies have shown that mononuclear cells (CD4+ and CD8+ T cells, plasma cells and macrophages) infiltrate the vessel wall of patients with Takayasu arteritis. Play an important role in the pathogenesis process. CD4 and CD8 lymphocytes, natural killer cells and macrophages infiltrate the three layers of blood vessel walls by releasing inflammatory factors TNF-a, INF-γ, IL-6 and IL-17 as well as vascular endothelial growth factor (VEGF) and platelet growth factor Factors such as PDGF promote intima proliferation, thickening of blood vessel walls, or da...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06G01N2030/027G01N2030/062
Inventor 杜杰王媛李凤娟檀鑫王雪
Owner 北京豪思生物科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap